<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36631153</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>380</Volume><PubDate><Year>2023</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.</ArticleTitle><Pagination><StartPage>e072529</StartPage><MedlinePgn>e072529</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e072529</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj-2022-072529</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status.</AbstractText><AbstractText Label="DESIGN">Retrospective nationwide cohort study.</AbstractText><AbstractText Label="SETTING">Electronic medical records from an Israeli nationwide healthcare organisation.</AbstractText><AbstractText Label="POPULATION">1&#x2009;913&#x2009;234 Maccabi Healthcare Services members of all ages who did a polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 1 October 2021.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Risk of an evidence based list of 70 reported long covid outcomes in unvaccinated patients infected with SARS-CoV-2 matched to uninfected people, adjusted for age and sex and stratified by SARS-CoV-2 variants, and risk in patients with a breakthrough SARS-CoV-2 infection compared with unvaccinated infected controls. Risks were compared using hazard ratios and risk differences per 10&#x2009;000 patients measured during the early (30-180 days) and late (180-360 days) time periods after infection.</AbstractText><AbstractText Label="RESULTS">Covid-19 infection was significantly associated with increased risks in early and late periods for anosmia and dysgeusia (hazard ratio 4.59 (95% confidence interval 3.63 to 5.80), risk difference 19.6 (95% confidence interval 16.9 to 22.4) in early period; 2.96 (2.29 to 3.82), 11.0 (8.5 to 13.6) in late period), cognitive impairment (1.85 (1.58 to 2.17), 12.8, (9.6 to 16.1); 1.69 (1.45 to 1.96), 13.3 (9.4 to 17.3)), dyspnoea (1.79 (1.68 to 1.90), 85.7 (76.9 to 94.5); 1.30 (1.22 to 1.38), 35.4 (26.3 to 44.6)), weakness (1.78 (1.69 to 1.88), 108.5, 98.4 to 118.6; 1.30 (1.22 to 1.37), 50.2 (39.4 to 61.1)), and palpitations (1.49 (1.35 to 1.64), 22.1 (16.8 to 27.4); 1.16 (1.05 to 1.27), 8.3 (2.4 to 14.1)) and with significant but lower excess risk for streptococcal tonsillitis and dizziness. Hair loss, chest pain, cough, myalgia, and respiratory disorders were significantly increased only during the early phase. Male and female patients showed minor differences, and children had fewer outcomes than adults during the early phase of covid-19, which mostly resolved in the late period. Findings remained consistent across SARS-CoV-2 variants. Vaccinated patients with a breakthrough SARS-CoV-2 infection had a lower risk for dyspnoea and similar risk for other outcomes compared with unvaccinated infected patients.</AbstractText><AbstractText Label="CONCLUSIONS">This nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mizrahi</LastName><ForeName>Barak</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1053-4773</Identifier><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudry</LastName><ForeName>Tamar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaks-Manov</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yehezkelli</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkstein</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiva</LastName><ForeName>Pinchas</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekka-Zohar</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maccabi Healthcare Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben David</LastName><ForeName>Shirley Shapiro</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Maccabi Healthcare Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Uri</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Maccabi Healthcare Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bivas-Benita</LastName><ForeName>Maytal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenfeld</LastName><ForeName>Shira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Maccabi Healthcare Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36631153</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Coronavirus Disease WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/.</Citation></Reference><Reference><Citation>World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID-19: Variants of the Virus. 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19). https://www.who.int/health-topics/coronavirus.</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al. . Characterising long COVID: a living systematic review. BMJ Glob Health 2021;6:e005427. 10.1136/bmjgh-2021-005427&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. . 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 2021;398:747-58. 10.1016/S0140-6736(21)01755-4&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al. . 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021;9:747-54. 10.1016/S2213-2600(21)00174-0&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00174-0</ArticleId><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, et al. Bergen COVID-19 Research Group . Long COVID in a prospective cohort of home-isolated patients. Nat Med 2021;27:1607-13. 10.1038/s41591-021-01433-3&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Hallas J, Nielsen H, et al. . Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis 2021;21:1373-82. 10.1016/S1473-3099(21)00211-5&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr&#xf9; G, Bertelloni D, Diolaiuti F, et al. . Long-COVID Syndrome? A Study on the Persistence of Neurological, Psychological and Physiological Symptoms. Healthcare (Basel) 2021;9:575. 10.3390/healthcare9050575&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare9050575</ArticleId><ArticleId IdType="pmc">PMC8152255</ArticleId><ArticleId IdType="pubmed">34068009</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, et al. . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2021;373:n1098. 10.1136/bmj.n1098&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021;8:416-27. 10.1016/S2215-0366(21)00084-5&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open 2021;4:e2111417. 10.1001/jamanetworkopen.2021.11417&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021;27:601-15. 10.1038/s41591-021-01283-z&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, et al. . Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021;372:n693. 10.1136/bmj.n693&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 2022;103:154-62. 10.1016/j.bbi.2022.04.013&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Parkin A, Makower S, Greenwood DC. Post-COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross-sectional evaluation from a community COVID rehabilitation service. J Med Virol 2022;94:1419-27. 10.1002/jmv.27456&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27456</ArticleId><ArticleId IdType="pmc">PMC8661751</ArticleId><ArticleId IdType="pubmed">34783052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis 2022;226:1593-607. 10.1093/infdis/jiac136&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Cox RJ, Langeland N. Long COVID: A growing problem in need of intervention. Cell Rep Med 2022;3:100552. 10.1016/j.xcrm.2022.100552&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100552</ArticleId><ArticleId IdType="pmc">PMC8841141</ArticleId><ArticleId IdType="pubmed">35474749</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ 2021;374:n1648. 10.1136/bmj.n1648&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021;27:626-31. 10.1038/s41591-021-01292-y&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open 2021;4:e210830. 10.1001/jamanetworkopen.2021.0830&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, et al. . Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2021;76:399-401. 10.1136/thoraxjnl-2020-216086&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3march2022.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-15. 10.1056/NEJMoa2034577&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. COVE Study Group . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-16. 10.1056/NEJMoa2035389&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, et al. . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819-29. 10.1016/S0140-6736(21)00947-8&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, et al. . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021;384:1412-23. 10.1056/NEJMoa2101765&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101765</ArticleId><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med 2021;385:1393-400. 10.1056/NEJMoa2114255&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiou E, Simpson CR, Shi T, et al. . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397:1646-57. 10.1016/S0140-6736(21)00677-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00677-2</ArticleId><ArticleId IdType="pmc">PMC8064669</ArticleId><ArticleId IdType="pubmed">33901420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088. 10.1136/bmj.n1088&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. Ann Intern Med 2021;174:1334-6. 10.7326/M21-1976&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1976</ArticleId><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. The effectiveness of vaccination against long COVID A rapid evidence briefing. 2022. https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff.</Citation></Reference><Reference><Citation>Peghin M, De Martino M, Palese A, Graziano E, Isola M, Tascini C. &#x2018;Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients&#x2019;: authors&#x2019; response. Clin Microbiol Infect 2022;28:1397-8. 10.1016/j.cmi.2022.06.003&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.06.003</ArticleId><ArticleId IdType="pmc">PMC9279256</ArticleId><ArticleId IdType="pubmed">35842022</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro Ben David S, Cohen D, Karplus R, et al. . COVID-19 community care in Israel-a nationwide cohort study from a large health maintenance organization. J Public Health (Oxf) 2021;43:723-30. 10.1093/pubmed/fdab055&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdab055</ArticleId><ArticleId IdType="pmc">PMC7989272</ArticleId><ArticleId IdType="pubmed">33690854</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, Dagan N, Ben-Shlomo Y, et al. . Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021;385:1078-90. 10.1056/NEJMoa2110475&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hananel R, Fishman R, Malovicki-Yaffe N. Urban diversity and epidemic resilience: The case of the COVID-19. Cities 2022;122:103526. 10.1016/j.cities.2021.103526&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cities.2021.103526</ArticleId><ArticleId IdType="pmc">PMC8660207</ArticleId><ArticleId IdType="pubmed">34908641</ArticleId></ArticleIdList></Reference><Reference><Citation>Central Bureau of Statistics of the State of Israel. Characterization and classification of geographical units by the socio-economic level of the population 2015. 2019. https://www.cbs.gov.il/he/publications/DocLib/2019/1765_socio_economic_2015/e_print.pd.</Citation></Reference><Reference><Citation>Israeli Ministry of Health. The corona virus in Israel - a general picture. https://datadashboard.health.gov.il/COVID-19/general.</Citation></Reference><Reference><Citation>Ministry of Health. The British Variant is the Most Common Cause of COVID-19 Cases in Israel. 2021. https://www.gov.il/en/departments/news/30032021-01.</Citation></Reference><Reference><Citation>Israeli Ministry of Health. Discussion of the Management Team of Epidemics and the COVID-19 vaccines committee. 2021. https://www.gov.il/BlobFolder/reports/vaccine-priorities-board/he/files_publications_corona_vaccine-priorities-board-20062021.pdf.</Citation></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022;28:1461-7. 10.1038/s41591-022-01840-0&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan S, Khunti K, Alwan N. In the wake of the pandemic: preparing for long COVID. 2021. https://apps.who.int/iris/bitstream/handle/10665/339629/Policy-brief-39-1997-8073-eng.pdf?sequence=1.</Citation><ArticleIdList><ArticleId IdType="pubmed">33877759</ArticleId></ArticleIdList></Reference><Reference><Citation>Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. Circulation 2018;138:570-7. 10.1161/CIRCULATIONAHA.117.033065&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.033065</ArticleId><ArticleId IdType="pubmed">29588314</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. . Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021;6:100122. 10.1016/j.lanepe.2021.100122&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax 2021;76:405-7. 10.1136/thoraxjnl-2020-216377&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216377</ArticleId><ArticleId IdType="pmc">PMC7716295</ArticleId><ArticleId IdType="pubmed">33273028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkenborg Berg S, Dam Nielsen S, Nygaard U, et al. . Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 2022;6:240-8. 10.1016/S2352-4642(22)00004-9&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00004-9</ArticleId><ArticleId IdType="pmc">PMC8820960</ArticleId><ArticleId IdType="pubmed">35143771</ArticleId></ArticleIdList></Reference><Reference><Citation>Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. . Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health 2021;3:e360-70. 10.1016/S2589-7500(21)00077-7&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(21)00077-7</ArticleId><ArticleId IdType="pmc">PMC8166576</ArticleId><ArticleId IdType="pubmed">34045002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibiya K, Iwata H, Kinjo T, et al. . Incidence of common infectious diseases in Japan during the COVID-19 pandemic. PLoS One 2022;17:e0261332. 10.1371/journal.pone.0261332&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261332</ArticleId><ArticleId IdType="pmc">PMC8754328</ArticleId><ArticleId IdType="pubmed">35020724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856-63. 10.1111/j.1478-3231.2006.01311.x&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2006.01311.x</ArticleId><ArticleId IdType="pubmed">16911469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianci N, Subhani M, Hill T, et al. . Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. World J Hepatol 2022;14:1025-37. 10.4254/wjh.v14.i5.1025&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v14.i5.1025</ArticleId><ArticleId IdType="pmc">PMC9157703</ArticleId><ArticleId IdType="pubmed">35721296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54. 10.1038/s41579-020-00459-7&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Risk for COVID-19 Infection, Hospitalization, and Death By Age Group. 2022. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html.</Citation></Reference><Reference><Citation>de Souza AS, de Freitas Amorim VM, Guardia GDA, et al. . Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. Viruses 2022;14:827. 10.3390/v14040827&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14040827</ArticleId><ArticleId IdType="pmc">PMC9029021</ArticleId><ArticleId IdType="pubmed">35458557</ArticleId></ArticleIdList></Reference><Reference><Citation>Dol J, Boulos L, Somerville M, et al. . Health system impacts of SARS-CoV&#x2009;-&#x2009;2 variants of concern: a rapid review. BMC Health Serv Res 2022;22:544. 10.1186/s12913-022-07847-0&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-022-07847-0</ArticleId><ArticleId IdType="pmc">PMC9034743</ArticleId><ArticleId IdType="pubmed">35461246</ArticleId></ArticleIdList></Reference><Reference><Citation>DeGrace MM, Ghedin E, Frieman MB, et al. . Defining the risk of SARS-CoV-2 variants on immune protection. Nature 2022;605:640-52. 10.1038/s41586-022-04690-5&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04690-5</ArticleId><ArticleId IdType="pmc">PMC9345323</ArticleId><ArticleId IdType="pubmed">35361968</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022;399:2263-4. 10.1016/S0140-6736(22)00941-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. Vaccines (Basel) 2022;10:652. 10.3390/vaccines10050652&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>